NCT07577999Not yet recruitingEarly phase 1
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
Source: ClinicalTrials.gov · Last updated 23 Jul 2026
Brief summary (registry, in English)
This will be an open-label, single group supportive care pilot study in which patients are given cannabinoid gummies in the perioperative setting to alleviate RC/UD symptoms and improve quality of life. The primary objective will be to evaluate the safety and tolerability of a cannabigerol supplement used perioperatively (from 14 days prior to surgery to 30 days following surgery) by patients undergoing radical cystectomy with urinary diversion (RC/UD).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 4 May 2026
- Start date
- Jul 2027
- Primary completion date
- May 2028
- Lead sponsor
- Stanford University
- Diseases
- Bladder cancer
- NCT number
- NCT07577999
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 20
- From Jul 2027 to the primary completion date, May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have had heart attack or acute coronary syndrome in the 90 days prior to surgery
Other illness
- History of substance abuse
- History of psychosis or schizophrenia
Other
- CBD or Cannabigerol usage in the last 30 days
- THC usage in the last 30 days
- Pregnant or breastfeeding individuals
Who the study is looking for
- 18 years of age or older
- Non-metastatic bladder cancer scheduled to undergo radical cystectomy and urinary diversion
- Patient is able to understand consent and is willing and able to provide written informed consent
- Patient makes their own medical decisions
- Lives in state of California
- Patient is able and willing to refrain from using any non-study cannabis during the screening and treatment phases of the study
- Females of childbearing potential to utilize an acceptable birth control method while consuming the gelatin-based chewable medication
- Be able to read and understand the study questionnaires
- Patient agrees to not to operate heavy machinery or engage in activities that require mental alertness while taking the gelatin-based chewable cannabigerol medication, as these substances may cause drowsiness.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stanford University Coordinator of this site? Confirm its status | Palo Alto | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.